Detailed Information on Publication Record
2008
Fading of the inhibition of CYP2D6 after paroxetine treatment discontinuation
ŽOURKOVÁ, Alexandra, Jan JUŘICA, Eva MCCASKEY HADAŠOVÁ and Lucie PULKRÁBKOVÁBasic information
Original name
Fading of the inhibition of CYP2D6 after paroxetine treatment discontinuation
Name in Czech
Odeznění inhibice CYP2D6 po vysazení léčby paroxetinem
Authors
ŽOURKOVÁ, Alexandra (203 Czech Republic, guarantor), Jan JUŘICA (203 Czech Republic), Eva MCCASKEY HADAŠOVÁ (203 Czech Republic) and Lucie PULKRÁBKOVÁ (203 Czech Republic)
Edition
European Neuropsychopharmacology, Elsevier, 2008, 0924-977X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30000 3. Medical and Health Sciences
Country of publisher
Netherlands
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 3.661
RIV identification code
RIV/00216224:14110/08:00026387
Organization unit
Faculty of Medicine
UT WoS
000259593801012
Keywords in English
disinhibition; CYP2D6; paroxetine; poor metaboliser; phenotype; genotype
Tags
International impact, Reviewed
Změněno: 30/3/2010 08:50, prof. MUDr. Alexandra Žourková, CSc.
V originále
The study unswers an important question: how long persists the inhibition after paroxetine treatment? The inhibition of CYP2D6 could exclude any substrates of CYP2D6 from the therapy. 4 weeks period seem to be sufficient for restoration of metabolic activity of CYP2D6.
In Czech
Článek pojednává o odeznění inhibice CYP2D6 po vysazení léčby paroxetinem u pacientů s depresivní poruchou.Inhibice odezněla po 4, resp. 6 týdnech od vysazení paroxetinu.
Links
| MSM0021622404, plan (intention) |
|